The history of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial release generated massive returns, the expiration of its patent opened the door to off-brand competitors, https://socialclubfm.com/story12444705/the-copyright-and-big-pharma-a-precarious-investment